Title |
Benralizumab: a unique IL-5 inhibitor for severe asthma
|
---|---|
Published in |
Journal of Asthma and Allergy, April 2016
|
DOI | 10.2147/jaa.s78049 |
Pubmed ID | |
Authors |
Laren D Tan, Jennifer M Bratt, Dorottya Godor, Samuel Louie, Nicholas J Kenyon |
Abstract |
The presence of eosinophilic inflammation is a characteristic feature of chronic and acute inflammation in asthma. An estimated 5%-10% of the 300 million people worldwide who suffer from asthma have a severe form. Patients with eosinophilic airway inflammation represent approximately 40%-60% of this severe asthmatic population. This form of asthma is often uncontrolled, marked by refractoriness to standard therapy, and shows persistent airway eosinophilia despite glucocorticoid therapy. This paper reviews personalized novel therapies, more specifically benralizumab, a humanized anti-IL-5Rα antibody, while also being the first to provide an algorithm for potential candidates who may benefit from anti-IL-5Rα therapy. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 2 | 22% |
Ecuador | 1 | 11% |
United Kingdom | 1 | 11% |
United States | 1 | 11% |
Unknown | 4 | 44% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 4 | 44% |
Members of the public | 4 | 44% |
Scientists | 1 | 11% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 76 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 15 | 20% |
Student > Bachelor | 11 | 14% |
Student > Master | 9 | 12% |
Other | 9 | 12% |
Professor | 5 | 7% |
Other | 14 | 18% |
Unknown | 13 | 17% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 31 | 41% |
Pharmacology, Toxicology and Pharmaceutical Science | 11 | 14% |
Agricultural and Biological Sciences | 8 | 11% |
Biochemistry, Genetics and Molecular Biology | 5 | 7% |
Immunology and Microbiology | 4 | 5% |
Other | 6 | 8% |
Unknown | 11 | 14% |